Development and Evaluation of a PSMA-Targeted Nanosystem Co-Packaging Docetaxel and Androgen Receptor siRNA for Castration-Resistant Prostate Cancer Treatment

Development and Evaluation of a PSMA-Targeted Nanosystem Co-Packaging Docetaxel and Androgen Receptor siRNA for Castration-Resistant Prostate Cancer Treatment

Primary prostate cancer (PC) progresses to castration-resistant PC (CRPC) during androgen deprivation therapy (ADR) in early stages of prostate cancer. Thus, rather than blocking the androgen-related pathway further, docetaxel (DTX)-based therapy has become the most effective and standard first-line...

Full description

Bibliographic Details
Main Authors: Yingying Zhang, Hongxia Duan, Heming Zhao, Lingling Qi, Yanhong Liu, Zheao Zhang, Chao Liu, Liqing Chen, Mingji Jin, Youyan Guan, Zhonggao Gao, Wei Huang
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Pharmaceutics
Subjects:
prostate cancer
androgen receptor
siRNA delivery
docetaxel
PSMA targeting
Online Access:https://www.mdpi.com/1999-4923/14/5/964

Internet

https://www.mdpi.com/1999-4923/14/5/964

Similar Items